Connect with us ! Google+ LinkedIn Pinterest YouTube

Bioactive Folate in the Treatment of Depression

Share on Facebook72Tweet about this on TwitterShare on LinkedIn35Share on Google+0Pin on Pinterest1Email this to someone

Depression is a mood disorder that approximately 1 in 8 Canadians will experiencdepressione at some point during their lifetime. Symptoms vary but often include feelings of sadness, sleep difficulties, fatigue, lack of motivation, loss of interest and withdrawal from friends and family. As you can imagine, depression can have quite a negative impact on an individual’s quality of life.
Unfortunately, there are not great solutions for treating depression. Selective serotonin reuptake inhibitors (SSRI’s) are a class of pharmaceutical drugs that have been used for decades to manage depression, although often with unsatisfactory results and a wide spectrum of side effects. In fact, much research has shown that patients taking an SSRI for mild or moderate depression do not find significant improvement. Moreover, a recent study found that mice with a complete inability to synthesize serotonin did not exhibit depressive behaviors as expected, questioning the idea that serotonin is the sole neurotransmitter affected in this mood disorder.

Perhaps it makes more sense to provide nutrients and co-factors that the body uses in multiple physiological pathways, thereby affecting numerous neurotransmitters instead of artificially elevating only one? One of these key nutrients for treating depression is folic acid; more specifically, the bioactive form that can enter the central nervous system called 5-methyltetrahydrofolate (5-MTHF).

Low levels of 5-MTHF in the bloodstream have long been found in populations of depressed individuals. This led researchers to test the hypothesis that low levels of 5-MTHF may contribute to the incidence of depression. Studies since have confirmed that 5-MTHF is a viable and extremely safe treatment option for depression as a stand-alone therapy, and also in combination with SSRI drugs. In fact, for individuals that respond poorly to SSRI’s, 5-MTHF is particularly indicated and has been shown to increase the drug’s effectiveness.

Why 5-MTHF instead of regular folic acid?
Research has found that a certain percentage of the population has a suboptimal ability to convert regular folic acid into 5-MTHF because of a genetic variation. In fact, up to 20% of Caucasians have two copies of this gene while 40%-50% of the same population has one copy. With two copies, the body’s ability to convert folate to 5-MTHF is reduced by 60% (!) and studies have shown that people with two copies of the variant are more likely to suffer from depression. The latter group containing only one copy of the gene has their conversion ability reduced by 35%. The high prevalence of these genetic modifications suggests that 5-MTHF is the necessary form for supplementation in all individuals. Quite simply, by giving folic acid instead of 5-MTHF, there is a significant risk that the body cannot convert or activate the vitamin at an efficient rate to keep up with the body’s demand.

The take home message here is that if you or someone you know suffer from depression, folic acid in the form of 5-MTHF should be considered as a safe and effective option. Speak with your health care practitioner about 5-MTHF, its dosage, and other nutrients that may be helpful for treating mood disorders.

Images by © 2014 Iain Campbell and 2012 themalni via DollarPhotoClub

References:

Angoa-Pérez M et al. Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype. ACS Chem Neurosci. 2014;5(10):908-19

Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev. 2008;13(3):216-26

Nelson JC. The Evolving Story of Folate in Depression and the Therapeutic Potential of L-Methylfolate. Am J Psychiatry 2012;169:12

Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012 Jul;57(7):406-13.

Papakostas GI et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267-74.

Public Health Agency of Canada. Accessed on Dec. 14th, 2014 at http://www.phac-aspc.gc.ca/cd-mc/mi-mm/depression-eng.php

Leave a Reply

Your email address will not be published. Required fields are marked *

Retype the CAPTCHA code from the image
Change the CAPTCHA codeSpeak the CAPTCHA code
 

Protected with IP Blacklist CloudIP Blacklist Cloud

JOIN US NOW
Purus sed vel ultricies, lorem rhoncus. Augue hac, adipiscing risus, sed ac? Pid nunc dignissim, non, ac parturient sociis enim.
Your Information will never be shared with any third party.
SUBSCRIBE TO NEWSLETTER
All rights reserved © Company Name, 2014
Dolor aliquet augue augue sit magnis, magna aenean aenean et! Et tempor, facilisis cursus turpis tempor odio, cursus montes ac turpis. Ultrices! Massa integer augue ridiculus adipiscing, massa cras pid. Turpis placerat scelerisque, vut odio mus non, mattis porttitor, nunc odio, turpis tortor sit? Pid amet, sed facilisis.
  • Goblinus globalus fantumo tandempo
  • Scelerisque cursus dignissim donus
  • Montes vutario lacus quis arcupolisio
  • Leftomato denitro oculus tepircos den
  • Spiratio dodenus christmas popupius
  • Afrenius globalus spiritum tandempo
  • Fitatos vutario lacus quis arcup delis
Here's $3 Off
Apply $3 off at checkout to any AOR product purchase. Just send your name and email and we'll email you your coupon.
Your Information will never be shared with any third party.
JOIN US NOW
Stay ahead of the curve with the latest AOR news, industry trends, and new product launches.
Your Information will never be shared with any third party.
Do you want massive traffic?
Dignissim enim porta aliquam nisi pellentesque. Pulvinar rhoncus magnis turpis sit odio pid pulvinar mattis integer aliquam!
  • Goblinus globalus fantumo tubus dia montes
  • Scelerisque cursus dignissim lopatico vutario
  • Montes vutario lacus quis preambul den lacus
  • Leftomato denitro oculus softam lorum quis
  • Spiratio dodenus christmas gulleria tix digit
  • Dualo fitemus lacus quis preambul pat turtulis
* we never share your e-mail with third parties.
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
COMPANY UPDATES
INDUSTRY TRENDS
PRODUCT LAUNCHES
Nutrition Education
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
Science-based facts from our team of top medical experts delivered right to your inbox!
Health Basics
Fitness Advice
JOIGNEZ-NOUS AUJOURD'HUI
Les dernières nouvelles:
AOR s’engage à protéger la confidentialité de vos données. Elles ne seront pas partagées avec des tiers. Vous pouvez vous désabonner à tout moment
MISE À JOUR
TENDANCES DE L'INDUSTRIE
LANCEMENTS DE PRODUITS
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
SPECIAL RETAILER OFFERS
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
MONTHLY PRICE LIST
JOIN US TODAY
For the latest:
AOR is committed to your privacy, your information will not be shared with any third party. You may unsubscribe at any time.
PRODUCT LAUNCHES